Jun 27, 2022 / 08:30PM GMT
Operator
Welcome to Kezar Life Sciences 2022 topline data presentation of the MISSION Phase 2 clinical trial. Today's presentation will be followed by a question-and-answer session. I would now like to hand the call over to John Fowler, Chief Executive Officer and Co-Founder of Kezar Life Sciences. Go ahead, John.
John Fowler - Kezar Life Sciences, Inc. - CEO & Co-Founder
Thank you for the introduction, Alex, and good afternoon, everyone. Thank you all for joining us today as we present the topline data for MISSION, our clinical trial investigating zetomipzomib for the treatment of lupus nephritis.
Here are our disclaimers.
Now, the second quarter has been very busy for us, having completed not one but two clinical trials. As you read from our press release, we have exciting, positive and meaningful results to share with you today, so I'm not going to delay jumping into the MISSION trial data. But here is the outline for the next hour.
Kezar just celebrated its seventh birthday, and it's been a true pleasure to work with my dear friend
Kezar Life Sciences Inc Topline Results from the MISSION Phase 2 Clinical Trial Evaluating Zetomipzomib - Corporate Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot